IWOW TECHNOLOGY LIMITED
Company Registration No. 199905973K
(Incorporated in the Republic of Singapore)
(the "**Company**")

MINUTES OF THE EXTRAORDINARY GENERAL MEETING OF THE COMPANY HELD AT 1004 TOA PAYOH NORTH, #02-17, SINGAPORE 318995 ON THURSDAY, 16 JULY 2026 AT 2:00 P.M.

PRESENT

DIRECTORS

Mr Soo Kee Wee	:	Chairman and Non-Executive Director
Mr Bo Jiang Chek Raymond	:	Chief Executive Officer and Executive Director
Mr Ang Swee Tian	:	Lead Independent Director
Mr Liew Kok Oon	:	Independent Director
Ms Thong Yuen Siew Jessie	:	Independent Director

IN ATTENDANCE / BY INVITATION

As per attendance record maintained by the Company.

SHAREHOLDERS

As per attendance record maintained by the Company.

QUORUM

As there was a quorum, Mr Soo Kee Wee ("**Mr Soo**") the Non-Executive Chairman, called the Extraordinary General Meeting of the Company (the "**Meeting**") to order at 2:00 p.m.

NOTICE

The Notice convening the Meeting dated 1 July 2026 was taken as read.

INTRODUCTION

Unless otherwise defined, all capitalised terms used herein shall bear the same meanings as ascribed to them in the Circular dated 1 July 2026.

Mr Soo welcomed all shareholders and attendees to the Meeting and introduced the Directors and the Chief Financial Officer (the "**CFO**") to the shareholders. The representatives from the Sponsor, Evolve Capital Advisory, Placement Agent, ZICO Capital Pte Ltd and the Company Secretaries were also present at the Meeting.

Mr Soo invited Mr Bo Jiang Chek Raymond, the Company's Chief Executive Officer and Executive Director ("**Mr Bo**" or the "**CEO**"), to chair the Meeting in his place.

OPENING ADDRESS

Mr Bo ("**Chairman**" of the Meeting) informed that the sole resolution to be tabled at the Meeting would be voted on by poll in accordance with the Company's Constitution and the Catalist Rules. The poll voting process would be conducted after the resolution has been duly proposed and seconded.

The Chairman informed the Meeting that he had been appointed as proxy by certain shareholders and would vote in accordance with their instructions. He further informed the Meeting that he would be proposing the resolution tabled at the Meeting.

The Company had appointed B.A.C.S. Private Limited as the polling agent and CACS Corporate Advisory Pte. Ltd. as the scrutineer to conduct and assist with the poll voting process at the Meeting. The Chairman also informed the shareholders that the Company had not received any questions from the shareholders prior to the EGM.

The Chairman then proceeded with the sole Agenda item of the Meeting, which was to seek the shareholders' approval on the Proposed Placement.

ORDINARY RESOLUTION: THE PROPOSED PLACEMENT

The agenda of the Meeting was to seek shareholders' approval for the Proposed Placement and authorised the Directors to allot and issue up to 66,667,000 Placement Shares at S$0.225 per Placement Share. All pertinent information on the Proposed Placement was set out in the Circular, including the rationale. The full text of the resolution can be found in the Notice of EGM.

The following motion was proposed by the Chairman and seconded by a shareholder:

That:

a. pursuant to section 161 of the Companies Act and Rules 805(1) and 811(3) of the Catalist Rules, approval be and is hereby given to the Directors to allot and issue up to 66,667,000 Placement Shares in such manner and on such terms and conditions as the Directors may in their absolute discretion deem fit, and at the Placement Price of S$0.225 per Placement Share for an aggregate consideration of up to approximately S$15,000,075

b. the Directors or any of them be and are hereby authorised to complete and do all acts and things (including, without limitation, enter into all transactions, arrangements and agreements and approve, sign and execute all such documents which they in their absolute discretion consider to be necessary, and to exercise such discretion as may be required, to approve any amendments, alterations or modifications to any documents, and to sign, file and/or submit any notices, forms and documents with or to the relevant authorities) as they or each of them deem desirable, necessary or expedient to give effect to the matters contemplated by this resolution and the Proposed Placement as they or each of them may in their or each of their absolute discretion deem fit in the interests of the Company; and

c. any acts and things done or performed, and/or any agreements and documents signed, executed, sealed and/or delivered by a Director in connection with this resolution and the Proposed Placement be and are hereby approved, confirmed and ratified.

The Chairman then invited Shareholders to raise questions. During the Q&A session, several shareholders raised questions and the responses provided by the Board were as follows:

No.	Questions from Shareholders	Responses
1.	Why the Company had chosen to undertake a placement to raise funds instead of other fundraising methods, such as a rights issue?	The CEO explained that the Board had considered various fundraising options, including a rights issue, bank financing, and other financing methods, before deciding to proceed with the Proposed Placement The Company was seeking to raise approximately S$15 million and given its substantial size, the Board considered a placement to be the most appropriate and efficient method. In relation to the rights issue, the CEO explained that one of the key considerations was the longer timeframe required to complete the exercise. In addition, there would be less certainty of successfully raising the full amount required, as a rights issue would require participation from a large number of shareholders, some of whom may choose not to subscribe for their entitlements or may instead renounce their rights. These additional processes could prolong the fundraising timeline and reduce the certainty of completing the fundraising successfully.

2.	Would existing shareholders be able to participate in the Proposed Placement, given that the Company has appointed a placement agent for the Proposed Placement?	The representative from ZICO Capital Pte. Ltd., the Placement Agent, responded that the bookbuilding would commence after the conclusion of the EGM, together with the sub-placement agent, Maybank Securities. The Placement Agent further explained that existing shareholders who wished to participate in the Proposed Placement could contact the Placement Agent to express their interest. Any such interest would be considered by the Placement Agent as part of the overall bookbuilding and allocation process.
3.	Could you please explain the basis for the discount offered in this placement compared to the current market price?	The CEO explained that the Placement Price was established through an iterative price discovery process, taking into account factors including the Company's prevailing market price, historical trading performance, trading liquidity, placement size and objective of broadening its shareholder base through the introduction of quality institutional and strategic investors. The Company had consulted several capital markets intermediaries, who conducted confidential market sounding with prospective investors to assess investor appetite, prevailing market conditions, pricing considerations and the likely execution parameters for a successful placement. Accordingly, the Board determined the final placement price after considering the recommendations of the Placement Agent together with the market feedback obtained through this process, with the objective of achieving an appropriate balance between minimising dilution to existing shareholders, achieving execution certainty and completing a meaningful fundraising.
4.	Looking at the proposed use of proceeds, the funding requirements do not appear to be particularly urgent. The Company has only recently acquired The Gentle Group, so would it not be more prudent to focus on integrating that business? Similarly, the proposed allocation for R&D does not seem to require immediate funding. Given that the Company is cash flow positive and continues to secure new contracts, could you explain why it is necessary to undertake this fundraising now, rather than when the need becomes more immediate?	The CEO clarified that approximately S$2 million will be utilised to partially fund the consideration for the acquisition of The Gentle Group and the post-acquisition integration activities. He further explained that an additional S$5 million approximately will be utilised for a new production facility for Gentle Foods. The facility would incorporate advanced automation technologies and focus on producing therapeutic meals and clinical nutrition products for hospitals, nursing homes, and senior care centres. This investment was particularly urgent as the existing production facility had already reached full operating capacity and could no longer support further expansion. He noted that demand for Gentle Food’s products is expected to grow continually, and recent developments in the healthcare sector have further reinforced this need. For instance, following regulatory actions against certain nursing homes for non-compliance issues, including the use of expired food ingredients, we were engaged to support the authorities and affected operators. Expanding the Company's production capacity was critical to enabling the Company to capture these growth opportunities, maintain the quality of its products and services, and meet the increasing demands of Singapore's healthcare and eldercare sectors.

		The CEO further explained that the other two key areas for the use of the proceeds are research and development (“R&D”) and business growth initiatives. Innovation has always been a key driver of the Group’s success. He said that the Company’s ability to secure new contracts had consistently depended on its capacity to develop new products and technologies. Although certain R&D projects could potentially be deferred, the Company was of the view that there were significant market opportunities currently available which should be actively pursued. The CFO added that the Group will also invest in R&D for Gentle Foods to develop more SKUs in relation to texture-modified food solutions, therapeutic food solutions for conditions such as Chronic Kidney Diseases, and shelf stable food products, which has high export potential to support its growth locally and beyond Singapore.
5.	Just to clarify, is 35% of the S$15 million intended for fixed assets, or is it being used for other purposes?	The CEO clarified that while the Company would not be acquiring a property for the new production facility, fixed assets (including specialised production equipment) will be acquired. Besides renovation works, the Company plans to invest in automation and software development initiatives to streamline processes and enhance overall operational efficiency for the new facility.
6.	Could the Company reduce R&D costs by collaborating with universities or acquiring existing technologies and products instead of developing them entirely in-house?	The CEO explained that the Company’s R&D team was lean and comprised specialists across various disciplines including electronics, software and firmware. As a factory-less technology company, the Company leveraged manufacturing capabilities and subcontractors based in China to achieve cost efficiencies while relying on its in-house team to focus on the development of its core technologies. Non-critical technology modules were outsourced where appropriate to optimise resources and operational efficiency. However, maintaining an in-house R&D function remained essential, as the Company’s competitive advantage lies in its ability to customise and innovate products to meet customers specific requirements. This capability had been a key factor in securing long-term contracts, including the Singapore Prisons, Ministry of Home Affairs project. He further explained that the Company’s in-house R&D team focused on product architecture, platform design and core technology development, while certain execution and development support functions were outsourced to specialized partners in China This approach enabled the Company to maintain its technological edge while benefiting from cost efficiencies.
7.	Would the Company retain ownership of the intellectual property where development work was sub-contracted to third parties while the Company retained responsibility for the product architecture and design?	The CEO replied that the Company’s software was protected by copyright, and that the Company also sought patent protection, where appropriate, to safeguard the Group’s intellectual property.

8.	Given the success of the prison tracker solution, is the Company selling it overseas, and if so, in which countries and at what volumes?	The CEO updated that the have been actively pursuing opportunities in several markets. He further explained that the adoption of electronic monitoring solutions is dependent on each country's legal and regulatory framework, particularly whether the legislation allows early release or community supervision supported by electronic monitoring. The Company remains positive with the progress in potential markets. For instance, Malaysia is progressing with the relevant legislative changes which is expected to be tabled for Parliamentary approval soon. The Company will share any relevant material developments in due course.
9.	Given the Board's expertise is primarily in electrical, mechanical, and electronic engineering, who is the nutrition expert leading this initiative? Additionally, what gives management confidence in the success of the venture, particularly in light of the planned S$4–5 million investment?	The CEO shared that the business would be led by Dr Shen Yiru, a PhD holder and the founder of The Gentle Group. He explained that the target company had established a strong market position as an early adopter of the International Dysphagia Diet Standardisation Initiative ("**IDDSI**") Standards, which has become a requirement for hospitals and nursing homes in Singapore. He further shared that, Dr Shen Yiru will be appointed as an Executive Officer of iWOW Group under a 5-years service agreement. She will continue to lead the business with the support of her experienced management team. He added that Dr Shen has also received iWOW shares as part of the consideration. The CEO stated that the Board is confident in the prospects of the business, having regard to its first-mover advantage, strong industry expertise, established customer base and favourable regulatory developments that are expected to support its future growth. He further elaborated on the synergies, including the plan for iWOW to leverage its technological capabilities to develop software solutions that automate workflows, improve accuracy, enhance operational efficiency and support future scalability through artificial intelligence and automation.
10.	A shareholder asked whether, once the Company secured a customer, such as a hospital, would its strategy be to cross-sell multiple products and services to the same customer, rather than supplying a single product or service.	The CEO explained that the Group does envisage strong cross-selling potential within the longevity economy by offering a combination of technological solutions covering senior safety, connectivity and therapeutic nutrition solutions. Different customer segments, such as hospitals, active ageing centres ("**AAC**"), and consumers, have varying needs, and the Group is exploring tailored offerings, including motion sensors and monitoring technologies. While many companies focus on individual areas such as senior safety, food solutions, or social engagement, the Group's key differentiator is its integrated platform that offers all three. This holistic approach has attracted interest from AAC operators, who see value in using technology to monitor isolated seniors and enable timely intervention when unusual inactivity is detected.

As there were no further questions from the shareholders, the Chairman invited the representative from CACS Corporate Advisory Pte. Ltd to explain the poll voting procedures to the shareholders.

POLLING

Shareholders were requested to complete the poll voting slips and hand the duly completed slips to the Scrutineer for verification and the counting of votes.

The Meeting was adjourned briefly to allow the Scrutineer to verify and count the votes before the poll results were announced.
.

RESULTS OF THE POLL VOTING

Upon the completion of the verification and counting of the votes, the results of the poll were handed to the Chairman. The Chairman then announced the results of the poll as follows:

Resolution number and Resolution Details		Total number of shares represented by votes for and against the relevant resolution	FOR		AGAINST	
			Number of shares	As a percentage of total number of votes for and against the resolution (%)	Number of shares	As a percentage of total number of votes for and against the resolution (%)
1	Resolution 1: To approve the Proposed Placement	173,517,456	173,517,456	100	0	0

Based on the poll results as verified and confirmed by the Scrutineer, the Chairman declared that the ordinary resolution tabled at the Meeting had been duly carried and passed

CONCLUSION

There being no other business to transact, the Chairman thanked everyone for attending the Meeting and declared the Meeting of the Company closed at 2:45 p.m.

Confirmed as True Record of Proceedings held

Bo Jiang Chek Raymond
Chairman of the Meeting